Mesa Laboratories(MLAB) - 2025 Q4 - Annual Results

Revenue Growth - Quarterly revenues for 4Q25 were $62,135, representing a 5.5% increase compared to 4Q24, with core organic revenues growth of 6.3%[9] - Full fiscal year revenues for FY25 reached $240,978, an 11.5% increase from FY24, with core organic revenues growth of 5.0%[10] - The Sterilization and Disinfection Control division generated revenues of $24,749 in 4Q25, with core organic revenues growth of 10.3%[12] - The Biopharmaceutical Development division saw a 20.3% increase in core organic revenues for FY25, driven by increased spending on capital equipment in North America and Europe[15] - Clinical Genomics division revenues for 4Q25 were $11,511, with core organic revenues growth of 4.4%, but a decline of 10.1% for the full year due to regulatory challenges in the China market[16] - Organic revenues growth for the year ended March 31, 2025, was 4.6%, while total revenues growth was 11.5%[31] Financial Performance - Adjusted operating income (AOI) for FY25 increased 12.3% year over year to 23.5% as a percentage of revenues, despite a significant rise in performance-based compensation expenses[4] - Cash flows from operations for FY25 totaled $46,808, with free cash flow of $42,559 primarily used to pay down debt[3] - Gross profit for the year ended March 31, 2025, was $150,870,000, representing a 13.3% increase from $133,250,000 in 2024[26] - The company reported a net loss of $7,114,000 for the three months ended March 31, 2025, compared to a net loss of $254,583,000 in the same period of 2024[26] - Non-GAAP adjusted operating income (AOI) for the three months ended March 31, 2025, was $12,104,000, slightly down from $12,336,000 in 2024[29] Asset Management - The company reduced inventories by 22.4% compared to the prior year, enhancing its ability to manage debt[4] - The company’s total assets decreased to $433,348,000 as of March 31, 2025, from $446,796,000 in 2024[28] - Stockholders' equity increased to $159,830,000 as of March 31, 2025, compared to $145,393,000 in 2024[28] Strategic Initiatives - Mesa Labs fully integrated GKE into its corporate infrastructure within nine months and exceeded acquisition commitments for revenues and profitability[5] - The company implemented Salesforce CRM across all sales teams, contributing to accelerated bookings growth[5] Market Outlook - The company anticipates continued growth in revenues and operating performance, despite uncertainties in the market environment[24] Impairment - The company experienced a significant impairment of goodwill and long-lived assets amounting to $274,533,000 in the year ended March 31, 2024[26] Shareholder Information - The weighted average common shares outstanding for the three months ended March 31, 2025, was 5,439,000, compared to 5,394,000 in the same period of 2024[29]